MediGene Receives Further European Patent on EndoTAG(TM)-1





Patent renews coverage and expands the protected territory




Martinsried/Munich, October 5, 2009. The biotech company MediGene AG (Frankfurt: MDG, Prime Standard, TecDAX) has obtained an extensive patent (no. 1530465) from the European Patent Office on the manufacturing process for the drug candidate EndoTAG(TM)-1. The patent protects the manufacturing process used for EndoTAG(TM)-1, including the drying step applied, products manufactured by the specified steps, products with identical properties, as well as further specified dried cationic liposomal compounds. The term of the patent "Method of producing a cationic liposomal preparation comprising a lipophilic compound" ends on June 26, 2023.




Dr. Frank Mathias, Chief Executive Officer of MediGene AG: "This new patent is extremely important for MediGene and for the commercialization of EndoTAG(TM)-1. In addition to the good patent protection which we already possess for the EndoTAG(TM) technology in general and for EndoTAG(TM)-1 in particular, the manufacturing process and the dried formulation of our drug candidate are now also patented. Overall patent protection is renewed for the product in itself, and the protected territory has been enlarged by a number of European countries. Whereas EndoTAG(TM)-1 is administered in the form of a suspension, the drug will be commercialized in the form of a dried product, so the patent represents a major progress toward our future plans for commercialization."




About EndoTAG(TM)-1: The drug candidate EndoTAG(TM)-1 selectively attacks blood vessels needed for the growth of tumors. It is a novel combination of positively charged liposomes - minute globules of lipid molecules - and the embedded active substance paclitaxel. EndoTAG(TM)-1 is targeted to the negatively charged cells that are lining newly formed tumor blood vessels. Thus only tumor blood vessels are attacked without any harm to those in healthy tissue. At the same time EndoTAG(TM)-1 inhibits the development of new blood vessels, thus suppressing further tumor growth. The drug candidate has obtained orphan drug designation for Europe and the USA, granting benefits in the development and commercialization of drugs for the treatment of rare diseases.


In October 2008 MediGene reported positive results obtained in a clinical phase II trial of the drug candidate EndoTAG(TM)-1 for the treatment of pancreatic carcinoma. Since 2007, MediGene has been conducting another clinical phase II trial in the indication triple receptor-negative breast cancer, the results of which are expected in the first six months of 2010.




This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of MediGene as of the date of this release. These forward-looking statements are no guarantees for future performance, and the forward-looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements. MediGene(TM) and EndoTAG(TM) are trademarks of MediGene AG. This trademark may be held or licensed for specific countries.




- ends -




MediGene AG is a publicly listed (Frankfurt: MDG, Prime Standard, TecDAX) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company to have drugs on the market, which are being distributed by partner companies and has several drug candidates in clinical development, two of which provide significant sales potential. In addition, the company has numerous projects in research and pre-clinical development and possesses innovative platform technologies. MediGene focuses on the research and development of novel drugs for the treatment of cancer and autoimmune diseases




Contact MediGene AG




Fax: +49 - 89 - 85 65 - 2920


Julia Hofmann / Dr. Nadja Wolf, Public Relations, Tel.: +49 - 89 - 85 65 - 3324


Dr. Georg Dönges, Investor Relations, Tel.: +49 - 89 - 85 65 - 2946